查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1790429

美国办公室实验室市场规模、份额和趋势分析：按模式、服务、专业和细分市场预测，2025 年至 2033 年

U.S. Office-based Labs Market Size, Share & Trends Analysis Report By Modality (Single Specialty, Multi-Specialty), By Service (Cardiac, Endovascular Intervention, Venous), By Specialist, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

美国办公室实验室市场摘要

美国办公室实验室市场规模预计在 2024 年将达到 139 亿美元，预计到 2033 年将达到估计值亿美元，2025 年至 2033 年的复合年增长率为 11.16%。近年来，美国患者对办公室实验室的偏好日益增加，以及门诊手术介入的趋势日益增强，是推动市场成长的关键因素。办公室实验室 (OBL) 在转变医疗保健提供系统、支援医疗设备、设备和其他产品的成长方面发挥关键作用。快速变化的医疗保健提供格局正在推动主要市场参与者转变经营模式，以从持续转型中获得最大收益。

美国心血管和放射科手术数量的不断增长是门诊实验室 (OBL) 市场成长要素。根据《2024 年心臟病和中风统计报告》，近一半（48.6%）的美国人口患有某种形式的心血管疾病，例如心臟疾病、心臟衰竭、中风或高血压。日益加重的疾病负担导致对诊断和介入治疗的需求不断增长，从而促进了市场的成长。

周边动脉疾病尤其推动了门诊介入治疗的需求。根据美国心臟协会2022年的报告，周边动脉疾病(PAD)影响美国约850万40岁以上的人。周边动脉疾病通常需要微创血管介入治疗，例如血管成形术、切除术和置入术，这些治疗越来越多地在门诊进行。

第一章调查方法与范围

第二章执行摘要

  • 市场概述
  • 市场区隔
  • 市场区隔
  • 竞争格局

第三章市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 补贴市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 法规结构和报销方案
    • 法律规范
    • 赎回情景
  • 商业环境分析工具
    • 波特五力分析
    • PESTLE分析

第四章：美国办公室实验室市场：按模式的估计和趋势分析

  • 2024 年及 2033 年美国办公室实验室市场趋势及份额分析（按模式）
  • 美国办公室实验室市场细分仪表板（按模式）
  • 美国办公室实验室市场规模及预测（按模式）
    • 单一专业实验室
    • 多专业实验室
    • 混合实验室

第五章：美国办公室实验室市场：按服务进行的估算和趋势分析

  • 2024 年及 2033 年美国办公室实验室市场趋势及服务份额分析
  • 美国办公室实验室市场细分仪表板：按服务
  • 美国办公室实验室市场规模及服务预测
    • 週边血管介入治疗
    • 心
    • 介入放射学
    • 静脉
    • 血管内介入治疗
    • 其他的

第六章：美国办公室实验室市场：专业估算与趋势分析

  • 2024 年及 2033 年美国办公室实验室市场趋势及专业份额分析
  • 美国办公室实验室市场细分仪表板（按专业划分）
  • 美国办公室实验室市场规模及专业预测
    • 血管外科医师
    • 介入性心臟病学
    • 介入放射学
    • 其他的

第七章美国办公室实验室市场：竞争格局

  • 供应商竞争分类
  • 服务供应商竞争分类
  • 战略地图
  • 公司简介
Product Code: 2-68038-900-5

U.S. Office-based Labs Market Summary

The U.S. office-based labs market size was estimated at USD 13.90 billion in 2024 and is expected to reach an estimated value of USD 35.21 billion by 2033, growing at a CAGR of 11.16% from 2025 to 2033. Growing preference for office-based labs by patients in the U.S. in recent years and the increasing trend of performing surgical interventions in outpatient settings are among key factors driving the market growth. Office-based labs (OBLs) are playing a vital role in transforming the healthcare delivery system and are supporting the growth of medical devices, equipment, and other products.The rapidly transitioning healthcare delivery scenario is driving key market players to transform their business models to achieve maximum benefit from ongoing transition.

The rising number of cardiovascular and radiological procedures in the U.S. is a significant growth driver for the office-based labs (OBLs) market. Cardiovascular disease remains the leading cause of death in the U.S. A report from the 2024 Heart Disease and Stroke Statistics indicates that nearly half of the U.S. population (48.6%) has some form of cardiovascular disease, including coronary heart disease, heart failure, stroke, and high blood pressure. This growing disease burden is translating into an increased demand for diagnostic and interventional procedures, thereby supplementing market growth.

Peripheral artery disease in particular is fueling demand for outpatient interventional care. According to the American Heart Association report published in 2022, peripheral artery disease (PAD) affected approximately 8.5 million people aged 40 and in the U.S. Peripheral artery disease often requires minimally invasive vascular interventions, such as angioplasty, atherectomy, or stenting, which are increasingly being performed in outpatient settings.

U.S. Office-based Labs Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. office-based labs market report based on service, modality, and specialist:

  • Services Outlook (Revenue, USD Million, 2021 - 2033)
  • Peripheral Vascular Intervention
    • Atherectomy
    • Vascular Angioplasty
    • Stenting
    • Other PVI
  • Endovascular Interventions
  • Cardiac
  • Interventional radiology
    • Uterine Fibroid Embolization (UFE)
    • Prostate Artery Embolization (PAE)
    • Y90/Oncology
    • Other IR
  • Venous
    • RFA (Radiofrequency Ablation) and EVLT (Endovenous Laser Therapy)
    • Sclerotherapy/Glue
    • Venous Stenting
    • Other Deep Vein
  • Others
  • Services Outlook (Number of Procedures, 2021 - 2033)
  • Peripheral Vascular Intervention
    • Atherectomy
    • Vascular Angioplasty
    • Stenting
    • Other PVI
  • Endovascular Interventions
  • Cardiac
  • Interventional radiology
    • Uterine Fibroid Embolization (UFE)
    • Prostate Artery Embolization (PAE)
    • Y90/Oncology
    • Other IR
  • Venous
    • RFA (Radiofrequency Ablation) and EVLT (Endovenous Laser Therapy)
    • Sclerotherapy/Glue
    • Venous Stenting
    • Other Deep Vein
  • Others
  • Modality Outlook (Revenue, USD Million, 2021 - 2033)
  • Single Specialty
  • Multi-Specialty
  • Hybrid
  • Specialist Outlook (Revenue, USD Million, 2021 - 2033)
  • Vascular Surgeons
  • Interventional Cardiologists
  • Interventional Radiologists
  • Others

Chapter 01 Methodology And Scope

  • 1.1 Market Segmentation & Scope
  • 1.2 Segment Definitions
    • 1.2.1 Estimates And Forecast Timeline
  • 1.3 Research Methodology
    • 1.3.1 Information Procurement
      • 1.3.1.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
      • 1.3.2.1 Secondary Sources
      • 1.3.2.2 Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Three Pillars Of Market Estimation
      • 1.6.1.1 Secondary Market Research
      • 1.6.1.2 Primary Market Intelligence
        • 1.6.1.2.1. In-Depth Interviews (Idis)
        • 1.6.1.2.2. Online Survey Program
    • 1.6.2 Market Modeling & Forecasting
      • 1.6.2.1 Procedure Volume Estimation (2021-2024)
      • 1.6.2.2 Average Cost Estimation (2021-2024)
      • 1.6.2.3 Forecasting (2025-2033)
      • 1.6.2.4 Segment Share Analysis
  • 1.7 List Of Secondary Sources
  • 1.8 List Of Abbreviations
  • 1.9 Objectives
    • 1.9.1 Objective - 1
    • 1.9.2 Objective - 2
    • 1.9.3 Objective - 3

Chapter 02 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Market Segmentation
  • 2.3 Market Segmentation
  • 2.4 Competitive Landscape

Chapter 03 Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Increasing Volume Of Cardiovascular And Radiological Procedures
        • 3.2.1.1.1. Case Study: Peripheral Vascular Interventions For Peripheral Artery Disease (Pad) In Office-Based Labs
      • 3.2.1.2 Growing Preference For Office-Based Labs Over Hospitals
        • 3.2.1.2.1. Case Study: Trends In Peripheral Vascular Interventions And The Rise Of Office-Based Laboratories In The U.S.
        • 3.2.1.2.2. Case Study: Utilization Patterns And Outcomes Of Pad Procedures In Office-Based Labs Versus Hospitals.
      • 3.2.1.3 Advancing Technology And Rising Preference For Minimally Invasive Procedures
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 High Risk Option For Severe Cases
      • 3.2.2.2 High Capital Investment And Operational Costs
    • 3.2.3 Market Opportunity Analysis
      • 3.2.3.1 Strategic Partnerships And Physician Ownership
    • 3.2.4 Market Challenges Analysis
      • 3.2.4.1 Competitive Pressure From Ambulatory Surgical Centers (Ascs) And Hospital Outpatient Departments (Hopds)
  • 3.3 Regulatory Framework & Reimbursement Scenario
    • 3.3.1 Regulatory Framework
    • 3.3.2 Reimbursement Scenario
  • 3.4 Business Environment Analysis Tools
    • 3.4.1 Porter's Five Forces Analysis
    • 3.4.2 Pestle Analysis

Chapter 04 U.S. Office-Based Labs Market: Modality Estimates & Trend Analysis

  • 4.1 U.S. Office-Based Labs Market: Modality Movement Share Analysis, 2024 & 2033
  • 4.2 U.S. Office-Based Labs Market: Modality Segment Dashboard
  • 4.3 U.S. Office-Based Labs Market Size & Forecast And Forecasts, By Modality (Usd Billion)
    • 4.3.1 Single Specialty Labs
      • 4.3.1.1 Single Specialty Labs Market, 2021 - 2033 (Usd Billion)
    • 4.3.2 Multi-Specialty Labs
      • 4.3.2.1 Multi-Specialty Labs Market, 2021 - 2033 (Usd Billion)
    • 4.3.3 Hybrid Labs
      • 4.3.3.1 Hybrid Labs Market, 2021 - 2033 (Usd Billion)

Chapter 05 U.S. Office-Based Labs Market: Service Estimates & Trend Analysis

  • 5.1 U.S. Office-Based Labs Market: Service Movement Share Analysis, 2024 & 2033
  • 5.2 U.S. Office-Based Labs Market: Service Segment Dashboard
  • 5.3 U.S. Office-Based Labs Market Size & Forecast And Forecasts, By Service (Usd Billion)
    • 5.3.1 Peripheral Vascular Intervention
      • 5.3.1.1 Reimbursement Scenario
      • 5.3.1.2 Peripheral Vascular Intervention Market, 2021 - 2033 (Usd Billion)
      • 5.3.1.3 Peripheral Vascular Intervention Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.1.4 Atherectomy
        • 5.3.1.4.1 Atherectomy Market, 2021 - 2033 (Usd Billion)
        • 5.3.1.4.2 Atherectomy Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.1.5 Vascular Angioplasty
        • 5.3.1.5.1 Vascular Angioplasty Market, 2021 - 2033 (Usd Billion)
        • 5.3.1.5.2 Vascular Angioplasty Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.1.6 Stenting
        • 5.3.1.6.1 Stenting Market, 2021 - 2033 (Usd Billion)
        • 5.3.1.6.2 Stenting Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.1.7 Other Pvi
        • 5.3.1.7.1 Other Pvi Market, 2021 - 2033 (Usd Billion)
        • 5.3.1.7.2 Other Pvi Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.2 Cardiac
      • 5.3.2.1 Reimbursement Scenario
      • 5.3.2.2 Cardiac Market, 2021 - 2033 (Usd Billion)
      • 5.3.2.3 Cardiac Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.3 Interventional Radiology
      • 5.3.3.1 Reimbursement Scenario
      • 5.3.3.2 Interventional Radiology Market, 2021 - 2033 (Usd Billion)
      • 5.3.3.3 Interventional Radiology Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.4 Uterine Fibroid Embolization (Ufe)
        • 5.3.3.4.1 Uterine Fibroid Embolization (Ufe) Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.4.2 Uterine Fibroid Embolization (Ufe) Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.5 Prostate Artery Embolization (Pae)
        • 5.3.3.5.1 Prostate Artery Embolization (Pae) Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.5.2 Prostate Artery Embolization (Pae) Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.6 Y90/Oncology
        • 5.3.3.6.1 Y90/Oncology Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.6.2 Y90/Oncology Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.7 Other Ir
        • 5.3.3.7.1 Other Ir Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.7.2 Other Ir Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.4 Venous
      • 5.3.4.1 Reimbursement Scenario
      • 5.3.4.2 Venous Market, 2021 - 2033 (Usd Million)
      • 5.3.4.3 Venous Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.4 Rfa (Radiofrequency Ablation) And Evlt (Endovenous Laser Therapy)
        • 5.3.3.4.1 Rfa (Radiofrequency Ablation) And Evlt (Endovenous Laser Therapy) Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.4.2 Urfa (Radiofrequency Ablation) And Evlt (Endovenous Laser Therapy) Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.5 Sclerotherapy/Glue
        • 5.3.3.5.1 Sclerotherapy/Glue Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.5.2 Sclerotherapy/Glue Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.6 Venous Stenting
        • 5.3.3.6.1 Venous Stenting Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.6.2 Venous Stenting Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.7 Other Deep Vein
        • 5.3.3.7.1 Other Deep Vein Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.7.2 Other Deep Vein Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.5 Endovascular Interventions
      • 5.3.5.1 Reimbursement Scenario
      • 5.3.5.2 Endovascular Interventions Market, 2021 - 2033 (Usd Million)
      • 5.3.5.3 Endovascular Interventions Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.6 Others
      • 5.3.6.1 Reimbursement Scenario
      • 5.3.6.2 Other Services Market, 2021 - 2033 (Usd Million)
      • 5.3.6.3 Other Services Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)

Chapter 06 U.S. Office-Based Labs Market: Specialist Estimates & Trend Analysis

  • 6.1 U.S. Office-Based Labs Market: Specialist Movement Share Analysis, 2024 & 2033
  • 6.2 U.S. Office-Based Labs Market: Specialist Segment Dashboard
  • 6.3 U.S. Office-Based Labs Market Size & Forecast And Forecasts, By Specialist (Usd Billion)
    • 6.3.1 Vascular Surgeons
      • 6.3.1.1 Vascular Surgeons Market, 2021 - 2033 (Usd Billion)
    • 6.3.2 Interventional Cardiologists
      • 6.3.2.1 Interventional Cardiologists Market, 2021 - 2033 (Usd Billion)
    • 6.3.3 Interventional Radiologists
      • 6.3.3.1 Interventional Radiologists Market, 2021 - 2033 (Usd Billion)
    • 6.3.4 Other Specialists
      • 6.3.4.1 Other Specialists Market, 2021 - 2033 (Usd Billion)

Chapter 07 U.S. Office-Based Labs Market: Competitive Landscape

  • 7.1 Suppliers' Competition Categorization
  • 7.2 Service Providers' Competition Categorization
    • 7.2.1 Company Market Position Analysis: Suppliers
    • 7.2.2 Company Market Position Analysis: Service Provider
  • 7.3 Strategy Mapping
    • 7.3.1 New Launch And Approval
    • 7.3.2 Acquisition
    • 7.3.3 Partnership & Collaboration
    • 7.3.4 Others
  • 7.4 Company Profiles
    • 7.3.1 Koninklijke Philips N.V.
      • 7.3.1.1 Company Overview
      • 7.3.1.2 Financial Performance
      • 7.3.1.3 Product/Service Benchmarking
      • 7.3.1.4 Strategic Initiatives
    • 7.3.2 Ge Healthcare
      • 7.3.2.1 Company Overview
      • 7.3.2.2 Financial Performance
      • 7.3.2.3 Product/Service Benchmarking
      • 7.3.2.4 Strategic Initiatives
    • 7.3.3 Siemens Healthineers Ag
      • 7.3.3.1 Company Overview
      • 7.3.3.2 Financial Performance
      • 7.3.3.3 Product/Service Benchmarking
      • 7.3.3.4 Strategic Initiatives
    • 7.3.4 Medtronic Plc
      • 7.3.4.1 Company Overview
      • 7.3.4.2 Financial Performance
      • 7.3.4.3 Product/Service Benchmarking
      • 7.3.4.4 Strategic Initiatives
    • 7.3.5 Boston Scientific Corporation
      • 7.3.5.1 Company Overview
      • 7.3.5.2 Financial Performance
      • 7.3.5.3 Product/Service Benchmarking
      • 7.3.5.4 Strategic Initiatives
    • 7.3.6 Abbott
      • 7.3.6.1 Company Overview
      • 7.3.6.2 Financial Performance
      • 7.3.6.3 Product/Service Benchmarking
      • 7.3.6.4 Strategic Initiatives
    • 7.3.7 Envision Healthcare Corporation (Kkr)
      • 7.3.7.1 Company Overview
      • 7.3.7.2 Financial Performance
      • 7.3.7.3 Product/Service Benchmarking
      • 7.3.7.4 Strategic Initiatives
    • 7.3.8 Surgical Care Affiliates (Sca)
      • 7.3.8.1 Company Overview
      • 7.3.8.2 Financial Performance
      • 7.3.8.3 Product/Service Benchmarking
      • 7.3.8.4 Strategic Initiatives
    • 7.3.9 Surgery Partners
      • 7.3.9.1 Company Overview
      • 7.3.9.2 Financial Performance
      • 7.3.9.3 Product/Service Benchmarking
      • 7.3.9.4 Strategic Initiatives
    • 7.3.10 Cardiovascular Coalition
      • 7.3.10.1 Company Overview
      • 7.3.10.2 Financial Performance
      • 7.3.10.3 Product/Service Benchmarking
      • 7.3.10.4 Strategic Initiatives
    • 7.3.11 Th Medical
      • 7.3.11.1 Company Overview
      • 7.3.11.2 Financial Performance
      • 7.3.11.3 Product/Service Benchmarking
      • 7.3.11.4 Strategic Initiatives
    • 7.3.12 Vascular Care Group
      • 7.3.12.1 Company Overview
      • 7.3.12.2 Financial Performance
      • 7.3.12.3 Product/Service Benchmarking
      • 7.3.12.4 Strategic Initiatives
    • 7.3.13 Coastal Vascular Institute
      • 7.3.13.1 Company Overview
      • 7.3.13.2 Financial Performance
      • 7.3.13.3 Product/Service Benchmarking
      • 7.3.14.4 Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Type of procedures performed in OBLs
  • Table 4 Catheter Placement(s): Medicare base case coding scenarios
  • Table 5 Arterial Shunting Coil Embolization (if required): Medicare base case coding scenarios
  • Table 6 Hepatic Angiogram: Medicare base case coding scenarios
  • Table 7 Volume Imaging Options: Medicare base case coding scenarios
  • Table 8 CT Acquisition (maybe billed in conjunction with CPT 76377): Medicare base case coding scenarios
  • Table 9 Mapping Options: Medicare base case coding scenarios
  • Table 10 Codes applicable between mapping and treatment: Medicare base case coding scenarios
  • Table 11 Catheter Placement (Phase II): Medicare base case coding scenarios
  • Table 12 Hepatic Angiogram (Phase II): Medicare base case coding scenarios
  • Table 13 Tumor Embolization Phase II: Medicare base case coding scenarios
  • Table 14 Microspheres Administration: Authorized User Codes (AU)
  • Table 15 Post Treatment Imaging (Provider Preference): Medicare base case coding scenarios
  • Table 16 U.S. office-based labs market revenue estimates and forecast, by Modality, 2021 - 2033 (USD billion)
  • Table 17 U.S. office-based labs market revenue estimates and forecast, by Service, 2021 - 2033 (USD billion)
  • Table 18 U.S. office-based labs market revenue estimates and forecast, by Service, 2021 - 2033 (Number of Procedures)
  • Table 19 U.S. Peripheral Vascular Intervention (PVI) in OBLs market revenue estimates and forecast, by Service, 2021 - 2033 (USD Million)
  • Table 20 U.S. Peripheral Vascular Intervention (PVI) in OBLs market revenue estimates and forecast, by Service Type, 2021 - 2033 (Number of Procedures)
  • Table 21 U.S. venous procedures in OBLs market revenue estimates and forecast, by service type, 2021 - 2033 (USD Million)
  • Table 22 U.S. venous procedures in OBLs market revenue estimates and forecast, by service type, 2021 - 2033 (Number of Procedures)
  • Table 23 U.S. interventional radiology in OBLs market revenue estimates and forecast, by service type, 2021 - 2033 (USD Million)
  • Table 24 U.S. interventional radiology in OBLs market revenue estimates and forecast, by service type, 2021 - 2033 (Number of Procedures)
  • Table 25 U.S. office-based labs market revenue estimates and forecast, by Specialist, 2021 - 2033 (USD billion)
  • Table 26 Shortage of vascular surgeons by workload analysis

List of Figures

  • Fig. 1 U.S. office-based labs segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Research methodology framework
  • Fig. 10 Secondary research framework
  • Fig. 11 Secondary research framework
  • Fig. 12 Market snapshot
  • Fig. 13 Market segmentation
  • Fig. 14 Market segmentation
  • Fig. 15 Competitive landscape
  • Fig. 16 U.S. office-based labs market dynamics
  • Fig. 17 U.S. office-based labs market: Porter's five forces analysis
  • Fig. 18 U.S. office-based labs market: PESTLE analysis
  • Fig. 19 U.S. office-based labs market: Modality movement share analysis
  • Fig. 20 U.S. office-based labs market: Modality segment dashboard
  • Fig. 21 Single specialty labs market, 2021 - 2033 (USD Billion)
  • Fig. 22 Multi-specialty labs market, 2021 - 2033 (USD Billion)
  • Fig. 23 Hybrid market, 2021 - 2033 (USD Billion)
  • Fig. 24 U.S. office-based labs market: Service movement share analysis
  • Fig. 25 U.S. office-based labs market: Service segment dashboard
  • Fig. 26 Peripheral vascular intervention market, 2021 - 2033 (USD Billion)
  • Fig. 27 Peripheral vascular intervention procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 28 Atherectomy market, 2021 - 2033 (USD Billion)
  • Fig. 29 Atherectomy procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 30 Vascular angioplasty market, 2021 - 2033 (USD Billion)
  • Fig. 31 Vascular angioplasty procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 32 Stenting market, 2021 - 2033 (USD Billion)
  • Fig. 33 Stenting procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 34 Other PVI market, 2021 - 2033 (USD Billion)
  • Fig. 35 Other PVI procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 36 Cardiac market, 2021 - 2033 (USD Billion)
  • Fig. 37 Cardiac procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 38 Interventional radiology market, 2021 - 2033 (USD Billion)
  • Fig. 39 Interventional radiology procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 40 Uterine Fibroid Embolization (UFE) market, 2021 - 2033 (USD Billion)
  • Fig. 41 Uterine Fibroid Embolization (UFE) procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 42 Prostate Artery Embolization (PAE) market, 2021 - 2033 (USD Billion)
  • Fig. 43 Prostate Artery Embolization (PAE) procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 44 Y90/Oncology market, 2021 - 2033 (USD Billion)
  • Fig. 45 Y90/Oncology procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 46 Other IR market, 2021 - 2033 (USD Billion)
  • Fig. 47 Other IR procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 48 Venous market, 2021 - 2033 (USD Million)
  • Fig. 49 Venous procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 50 RFA (Radiofrequency Ablation) and EVLT (Endovenous Laser Therapy) market, 2021 - 2033 (USD Million)
  • Fig. 51 RFA (Radiofrequency Ablation) and EVLT (Endovenous Laser Therapy) procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 52 Sclerotherapy/Glue market, 2021 - 2033 (USD Million)
  • Fig. 53 Sclerotherapy/Glue procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 54 Venous stenting market, 2021 - 2033 (USD Million)
  • Fig. 55 Venous stenting procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 56 Other deep vein market, 2021 - 2033 (USD Million)
  • Fig. 57 Other deep vein procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 58 Endovascular interventions market, 2021 - 2033 (USD Million)
  • Fig. 59 Endovascular interventions procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 60 Other services market, 2021 - 2033 (USD Million)
  • Fig. 61 Other services procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 62 U.S. office-based labs market: Specialist movement share analysis
  • Fig. 63 U.S. office-based labs market: Specialist segment dashboard
  • Fig. 64 Vascular surgeons market, 2021 - 2033 (USD Billion)
  • Fig. 65 Interventional cardiologists market, 2021 - 2033 (USD Billion)
  • Fig. 66 Interventional radiologists market, 2021 - 2033 (USD Billion)
  • Fig. 67 Other specialists market, 2021 - 2033 (USD Billion)
  • Fig. 68 Suppliers' competition categorization
  • Fig. 69 Service providers' competition categorization
  • Fig. 70 Company market position analysis: Suppliers
  • Fig. 71 Company market position analysis: Service providers
  • Fig. 72 Strategy mapping